| | | | | | | | | | | | | | | | | | | | | |
<?xml version="1.0" encoding="windows-1252"?> |
<!-- XBRL document created with Toppan Merrill Bridge 10.2.0.4 --> |
<!-- Based on XBRL 2.1 --> |
<!-- Created on: 2/27/2023 3:29:53 PM --> |
<!-- Modified on: 2/27/2023 3:29:53 PM --> |
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance"> |
| <roleRef xlink:type="simple" xlink:href="cldx-20221231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.celldextherapeutics.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.celldextherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.celldextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20221231.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20221231.xsd#DisclosureMarketableSecuritiesDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20221231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20221231.xsd#DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20221231.xsd#DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetailsCalc2" roleURI="http://www.celldextherapeutics.com/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetailsCalc2" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20221231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20221231.xsd#DisclosureOtherLongTermLiabilitiesDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20221231.xsd#DisclosureIncomeTaxesSummaryDetailsCalc2" roleURI="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesSummaryDetailsCalc2" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20221231.xsd#DisclosureIncomeTaxesReconciliationDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20221231.xsd#DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <calculationLink xlink:role="http://www.celldextherapeutics.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638131085919770501"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638131085919770501" order="1" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638131085919770501"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638131085919770501" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638131085919770501" order="1" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent_638131085919770501"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638131085919770501" xlink:to="us-gaap_MarketableSecuritiesCurrent_638131085919770501" order="2" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_638131085919770501"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638131085919770501" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_638131085919770501" order="3" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638131085919770501"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638131085919770501" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638131085919770501" order="4" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638131085919770501"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638131085919770501" order="2" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638131085919770501"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638131085919770501" order="3" use="optional" weight="1" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638131085919770501"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638131085919770501" order="4" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638131085919780467"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638131085919780467" order="5" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638131085919780467"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638131085919780467" order="1" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638131085919780467"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638131085919780467" xlink:to="us-gaap_LiabilitiesCurrent_638131085919780467" order="1" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638131085919780467"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638131085919780467" xlink:to="us-gaap_AccountsPayableCurrent_638131085919780467" order="1" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638131085919780467"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638131085919780467" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638131085919780467" order="2" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638131085919780467"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638131085919780467" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638131085919780467" order="3" use="optional" weight="1" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638131085919780467"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638131085919780467" xlink:to="us-gaap_OtherLiabilitiesCurrent_638131085919780467" order="4" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638131085919780467"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638131085919780467" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638131085919780467" order="2" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638131085919790467"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638131085919780467" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638131085919790467" order="3" use="optional" weight="1" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638131085919790467"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638131085919790467" order="2" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638131085919790467"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638131085919790467" xlink:to="us-gaap_PreferredStockValue_638131085919790467" order="1" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638131085919790467"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638131085919790467" xlink:to="us-gaap_CommonStockValue_638131085919790467" order="2" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638131085919790467"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638131085919790467" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638131085919790467" order="3" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638131085919790467"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638131085919790467" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638131085919790467" order="4" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638131085919790467"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638131085919790467" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638131085919790467" order="5" use="optional" weight="1"/> |
| | </calculationLink> |
| <calculationLink xlink:role="http://www.celldextherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638131085919800463"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638131085919800463" order="1" use="optional" weight="1" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638131085919800463"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638131085919800463" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638131085919800463" order="1" use="optional" weight="1" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638131085919800463"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638131085919800463" xlink:to="us-gaap_OperatingIncomeLoss_638131085919800463" order="1" use="optional" weight="1" priority="5"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638131085919800463"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638131085919800463" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638131085919800463" order="1" use="optional" weight="1" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_638131085919800463"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638131085919800463" xlink:to="us-gaap_CostsAndExpenses_638131085919800463" order="2" use="optional" weight="-1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638131085919800463"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638131085919800463" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638131085919800463" order="1" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_638131085919800463"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638131085919800463" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_638131085919800463" order="2" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638131085919800463"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638131085919800463" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638131085919800463" order="3" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement_638131085919810467"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638131085919800463" xlink:to="us-gaap_GainLossRelatedToLitigationSettlement_638131085919810467" order="4" use="optional" weight="-1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_638131085919810467"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638131085919800463" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_638131085919810467" order="5" use="optional" weight="-1" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome_638131085919810467"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638131085919800463" xlink:to="us-gaap_InterestAndOtherIncome_638131085919810467" order="2" use="optional" weight="1" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638131085919810467"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638131085919800463" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638131085919810467" order="2" use="optional" weight="-1" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_638131085919810467"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_638131085919810467" order="2" use="optional" weight="1" priority="4"/> |
| | </calculationLink> |
| <calculationLink xlink:role="http://www.celldextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638131085919810467"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638131085919810467" order="1" use="optional" weight="1" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638131085919810467"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638131085919810467" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638131085919810467" order="1" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638131085919810467"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638131085919810467" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638131085919810467" order="2" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_638131085919820469"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638131085919810467" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_638131085919820469" order="3" use="optional" weight="-1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638131085919820469"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638131085919810467" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638131085919820469" order="4" use="optional" weight="-1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_638131085919820469"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638131085919810467" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_638131085919820469" order="5" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_638131085919820469"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638131085919810467" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_638131085919820469" order="6" use="optional" weight="-1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638131085919820469"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638131085919810467" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638131085919820469" order="7" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638131085919820469"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638131085919810467" xlink:to="us-gaap_ShareBasedCompensation_638131085919820469" order="8" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_638131085919820469"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638131085919810467" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_638131085919820469" order="9" use="optional" weight="-1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638131085919820469"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638131085919810467" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638131085919820469" order="10" use="optional" weight="-1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638131085919820469"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638131085919810467" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638131085919820469" order="11" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_638131085919830466"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638131085919810467" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_638131085919830466" order="12" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_638131085919830466"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638131085919810467" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_638131085919830466" order="13" use="optional" weight="-1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638131085919830466"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638131085919830466" order="2" use="optional" weight="1" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_638131085919830466"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638131085919830466" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_638131085919830466" order="1" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_638131085919830466"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638131085919830466" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_638131085919830466" order="2" use="optional" weight="-1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638131085919830466"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638131085919830466" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638131085919830466" order="3" use="optional" weight="-1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_638131085919830466"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638131085919830466" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets_638131085919830466" order="4" use="optional" weight="1" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638131085919830466"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638131085919830466" order="3" use="optional" weight="1" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638131085919840466"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638131085919830466" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638131085919840466" order="1" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans_638131085919840466"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638131085919830466" xlink:to="us-gaap_ProceedsFromStockPlans_638131085919840466" order="2" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_638131085919840466"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638131085919830466" xlink:to="us-gaap_RepaymentsOfDebt_638131085919840466" order="3" use="optional" weight="-1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_638131085919840466"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638131085919830466" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_638131085919840466" order="4" use="optional" weight="1"/> |
| | </calculationLink> |
| <calculationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638131085919840466"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638131085919840466" order="1" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities_638131085919840466"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_MarketableSecurities_638131085919840466" order="2" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_638131085919850470"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_638131085919850470" order="1" use="optional" weight="1" priority="2"/> |
| | </calculationLink> |
| <calculationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Marketable Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_638131085919850470"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_638131085919850470" order="1" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20221231.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost_638131085919850470"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost_638131085919850470" order="2" use="optional" weight="1" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_638131085919850470"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_638131085919850470" order="1" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20221231.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_638131085919850470"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_638131085919850470" order="2" use="optional" weight="1" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20221231.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain_638131085919850470"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain_638131085919850470" order="1" use="optional" weight="1" priority="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20221231.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses_638131085919860468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses_638131085919860468" order="1" use="optional" weight="1" priority="1"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20221231.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses_638131085919860468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses_638131085919860468" order="2" use="optional" weight="1" priority="1"/> |
| | </calculationLink> |
| <calculationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Property and Equipment, Net (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638131085919860468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638131085919860468" order="1" use="optional" weight="1" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638131085919860468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638131085919860468" order="2" use="optional" weight="-1" priority="2"/> |
| | </calculationLink> |
| <calculationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Leases - Future minimum lease payments under non-cancellable leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638131085919860468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638131085919860468" order="1" use="optional" weight="1" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638131085919860468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638131085919860468" order="2" use="optional" weight="1" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638131085919860468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638131085919860468" order="3" use="optional" weight="1" priority="2"/> |
| | </calculationLink> |
| <calculationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetailsCalc2" xlink:type="extended" xlink:title="40702 - Disclosure - Leases - Future minimum lease payments under non-cancellable leases (Details) (Calc 2)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638131085919870469"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638131085919870469" order="1" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638131085919870469"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_OperatingLeaseLiability_638131085919870469" order="2" use="optional" weight="1"/> |
| | </calculationLink> |
| <calculationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638131085919870469"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638131085919870469" order="1" use="optional" weight="1" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20221231.xsd#cldx_AccruedResearchAndDevelopmentContractCostsCurrent" xlink:label="cldx_AccruedResearchAndDevelopmentContractCostsCurrent_638131085919870469"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="cldx_AccruedResearchAndDevelopmentContractCostsCurrent_638131085919870469" order="2" use="optional" weight="1" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638131085919870469"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638131085919870469" order="3" use="optional" weight="1" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638131085919870469"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638131085919870469" order="4" use="optional" weight="1" priority="2"/> |
| | </calculationLink> |
| <calculationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Other Long-Term Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities_638131085919880468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_638131085919880468" order="1" use="optional" weight="1" priority="3"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20221231.xsd#cldx_DeferredIncomeFromSaleOfTaxBenefits" xlink:label="cldx_DeferredIncomeFromSaleOfTaxBenefits_638131085919880468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilities" xlink:to="cldx_DeferredIncomeFromSaleOfTaxBenefits_638131085919880468" order="2" use="optional" weight="1" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_638131085919880468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_638131085919880468" order="3" use="optional" weight="1" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638131085919880468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_ContractWithCustomerLiability_638131085919880468" order="4" use="optional" weight="1" priority="3"/> |
| | </calculationLink> |
| <calculationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesSummaryDetailsCalc2" xlink:type="extended" xlink:title="41501 - Disclosure - Income Taxes - Summary (Details) Calc2" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20221231.xsd#cldx_IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance" xlink:label="cldx_IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance_638131085919880468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="cldx_IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance_638131085919880468" order="1" use="optional" weight="1" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20221231.xsd#cldx_ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" xlink:label="cldx_ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits_638131085919880468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cldx_IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance_638131085919880468" xlink:to="cldx_ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits_638131085919880468" order="1" use="optional" weight="1" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_638131085919880468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cldx_IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance_638131085919880468" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_638131085919880468" order="2" use="optional" weight="1" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_638131085919880468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cldx_IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance_638131085919880468" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_638131085919880468" order="3" use="optional" weight="1" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638131085919880468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638131085919880468" order="2" use="optional" weight="-1" priority="2"/> |
| | </calculationLink> |
| <calculationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails" xlink:type="extended" xlink:title="41502 - Disclosure - Income Taxes - Reconciliation (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638131085919890468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638131085919890468" order="1" use="optional" weight="1" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_638131085919890468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_638131085919890468" order="2" use="optional" weight="-1" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_638131085919890468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_638131085919890468" order="3" use="optional" weight="1" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_638131085919890468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_638131085919890468" order="4" use="optional" weight="1" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesOther" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingenciesOther_638131085919890468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingenciesOther_638131085919890468" order="5" use="optional" weight="1" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20221231.xsd#cldx_IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" xlink:label="cldx_IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits_638131085919890468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="cldx_IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits_638131085919890468" order="6" use="optional" weight="1" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638131085919890468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638131085919890468" order="7" use="optional" weight="1" priority="2"/> |
| | </calculationLink> |
| <calculationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="41503 - Disclosure - Income Taxes - Summary of deferred tax assets and liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638131085919900468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638131085919900468" order="1" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20221231.xsd#cldx_DeferredTaxAssetsLiabilitiesGross" xlink:label="cldx_DeferredTaxAssetsLiabilitiesGross_638131085919900468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="cldx_DeferredTaxAssetsLiabilitiesGross_638131085919900468" order="2" use="optional" weight="-1"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20221231.xsd#cldx_DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets" xlink:label="cldx_DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets_638131085919900468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cldx_DeferredTaxAssetsLiabilitiesGross_638131085919900468" xlink:to="cldx_DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets_638131085919900468" order="1" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638131085919900468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cldx_DeferredTaxAssetsLiabilitiesGross_638131085919900468" xlink:to="us-gaap_DeferredTaxAssetsGross_638131085919900468" order="2" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638131085919900468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638131085919900468" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638131085919900468" order="1" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638131085919900468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638131085919900468" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638131085919900468" order="2" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense_638131085919900468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638131085919900468" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpense_638131085919900468" order="3" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638131085919900468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638131085919900468" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638131085919900468" order="4" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638131085919900468"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638131085919900468" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638131085919900468" order="5" use="optional" weight="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_638131085919910469"/> |
| | <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638131085919900468" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_638131085919910469" order="6" use="optional" weight="1"/> |
| | </calculationLink> |
| </link:linkbase> |